Clinicopathological Research of Treatment of Hypopgaryngeal Cancer Based on Quality of Life

基于生活质量的下咽癌治疗的临床病理学研究

基本信息

项目摘要

1. As for the patients of hypopharyngeal cancer, their p53, Ki-67, PD-ECGF and VEGF were investigated. These tumor markers had no significant relationship with absence/presence of regional or distant recurrence after the initial treatment. These markers were regarded as no effective prognostic factors.2. To acquire better quality of life, laser debulking surgery prior to radiotherapy was conducted for T1T2 carcinoma of the hypopharynx. As a result, three-year local control rate, three-year larynx conservation rate, and three-year cause specific survival rate were 88%, 92%, and 92%, respectively. In addition, in patients who had undergone this procedure, few underwent tracheostomy, all could had oral diet from the next day of the operation, and none underwent total laryngectomy due to aspiration.3. Since some patients with carcinoma of the hypopharynx visit the hospital complaining of origin unknown neck tumor, the relationship between the site of neck metastasis and primary origin was investigated. As a result, when neck metastases were squamous cell carcinomas and were confined to upper or middle jugular areas, affected-side tonsillectomy was regarded as one of reliable methods to know the primary origin.4. Since carcinoma of the hypopharynx sometimes suffered from carcinoma of the tongue simultaneously, T1T2 carcinoma of the tongue was investigated. As a result, the prophylactic neck dissection would be indicated only when the patients and/or their family approved after detailed explanation about the advantage and disadvantage of this treatment. Supra-omohyoid neck dissection would be satisfactory as an initial treatment. Prognostic factors of neck metastases were depth of the invasion, vascular invasion, and muscular invasion of the primary tumor.
1.对下咽癌患者进行p53、Ki-67、PD-ECGF、VEGF的检测。这些肿瘤标志物与初始治疗后局部或远处复发的存在/不存在无显著关系。这些指标均不能作为有效的预后因素.为了提高患者的生活质量,我们对T1 T2下咽癌患者在放疗前进行了激光减积手术。结果,3年局部控制率、3年喉保存率和3年病因特异性生存率分别为88%、92%和92%。此外,在接受此手术的患者中,很少有患者接受气管切开术,所有患者从手术第二天起都可以口服饮食,没有患者因误吸而接受全喉切除术.由于部分下咽癌患者就诊时主诉颈部肿瘤来源不明,本文探讨颈部转移部位与原发肿瘤的关系。因此,当颈部转移瘤为鳞状细胞癌且局限于颈静脉上段或中段时,患侧扁桃体切除术是了解原发灶的可靠方法之一.由于下咽癌有时同时患有舌癌,因此研究了T1 T2舌癌。因此,只有在详细解释了这种治疗的优点和缺点后,患者和/或其家属同意时,才适用于预防性颈清扫术。肩胛舌骨上颈淋巴结清扫术作为初始治疗是令人满意的。颈部转移的预后因素是原发肿瘤的浸润深度、血管浸润和肌层浸润。

项目成果

期刊论文数量(59)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
梅野博仁,森一功,千々和圭一 他: "舌癌に対する予防的頸部郭清術の適応"耳鼻臨床. 93. 219-222 (2000)
Hirohito Umeno、Kazuhisa Mori、Keiichi Chijiwa 等人:“舌癌预防性颈清扫术的指征”耳鼻喉科 (Otorhinolaryngology) 93. 219-222 (2000)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
千々和圭一,森一功 他: "高齢喉頭癌患者のリンパ節転移への対応"喉頭. 12. 84-89 (2000)
Keiichi Chijiwa、Kazuko Mori 等:“老年喉癌患者淋巴结转移的管理”Laryngology. 12. 84-89 (2000)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
森一功: "頭頸部領域での内視鏡"耳鼻頭頸. 73. 91-97 (2001)
Kazunori Mori:“头颈部区域的内窥镜检查”《耳鼻喉科》73. 91-97 (2001)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Keiichi Chijiwa: "cervical metastasis from unknown primary carcinoma (in JAPANESE)"Head and Neck Cancer. 26. 17-22 (2000)
Keiichi Chijiwa:“不明原发癌的宫颈转移(日语)”头颈癌。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Naofumi Hayabuchi: "Head and neck cancer (in JAPANESE)"Jpn J Cancer Clin. 45. 315-316 (1999)
Naofumi Hayabuchi:“头颈癌(日语)”Jpn J Cancer Clin。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MORI Kazunori其他文献

MORI Kazunori的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MORI Kazunori', 18)}}的其他基金

A molecular scaffold HIC-5-and KLF4-dependent mechanism transactivates p21^<Cip1> in response to loss of anchorage
分子支架 HIC-5 和 KLF4 依赖性机制响应锚定丢失而反式激活 p21^<Cip1>
  • 批准号:
    22790327
  • 财政年份:
    2010
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Development of the Delivery System of English Learning Materials for Kosen Students of Elementary Level
小学科森英语学习资料传送系统的开发
  • 批准号:
    21720217
  • 财政年份:
    2009
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
The Development of an English Learning Video for Science and Engineering Education, and the Study of its Application
理工科英语学习视频的开发及应用研究
  • 批准号:
    17520412
  • 财政年份:
    2005
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Anatomical and Physiological studies of the laryngeal feedback system and it's control.
喉反馈系统及其控制的解剖学和生理学研究。
  • 批准号:
    08457458
  • 财政年份:
    1996
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)

相似海外基金

Development of new technologies for high-sensitivity detection of a B-cell tumor marker in DNA
开发高灵敏度检测 DNA 中 B 细胞肿瘤标志物的新技术
  • 批准号:
    10217428
  • 财政年份:
    2021
  • 资助金额:
    $ 2.05万
  • 项目类别:
The Role of AhR in carcinogenesis from inflammatory bowel disease and its usefulness as a novel tumor marker.
AhR 在炎症性肠病癌变中的作用及其作为新型肿瘤标志物的用途。
  • 批准号:
    21K15400
  • 财政年份:
    2021
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of novel tumor marker and targeting-antibody against pancreatic ductal adenocarcinoma
新型肿瘤标志物及胰腺导管腺癌靶向抗体的研制
  • 批准号:
    20H03527
  • 财政年份:
    2020
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of a Noninvasive Hepatocellular Carcinoma Tumor Marker Using Urine -Targeting Glycan Structures on Bikunin-
使用尿液靶向 Bikunin 上的聚糖结构开发非侵袭性肝细胞癌肿瘤标记物
  • 批准号:
    19K17445
  • 财政年份:
    2019
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Clinical appication of the melanoma specific novel tumor marker
黑色素瘤特异性新型肿瘤标志物的临床应用
  • 批准号:
    19K07720
  • 财政年份:
    2019
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of candidate tumor marker genes for pancreatic ductal adenocarcinoma by NGS-HiCEP method
NGS-HiCEP方法鉴定胰腺导管腺癌候选肿瘤标志物基因
  • 批准号:
    19K21342
  • 财政年份:
    2018
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Identification of serum tumor marker candidates by focused glycomic analyses
通过集中糖组分析鉴定候选血清肿瘤标志物
  • 批准号:
    18K07344
  • 财政年份:
    2018
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a universal tumor marker to diagnose the whole solid cancers
开发通用肿瘤标记物来诊断整个实体癌
  • 批准号:
    17K19893
  • 财政年份:
    2017
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Establishment of a new tumor marker of colorectal cancer that is a combination of high expression genes and low expression genes
高表达基因和低表达基因组合的结直肠癌新肿瘤标志物的建立
  • 批准号:
    16K19195
  • 财政年份:
    2016
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Prostaglandin E- major urinary metabolite (PGE-MUM) as a tumor marker for lung adenocarcinoma
前列腺素E-主要尿代谢物(PGE-MUM)作为肺腺癌的肿瘤标志物
  • 批准号:
    16K09558
  • 财政年份:
    2016
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了